We have been able to get in touch with the FDA and some of the manufacturers of the oral flea/tick preventatives that fall into the isoxazoline class – Bravecto, NexGard, Simperica and Credelio.
Here is some more clarity regarding the Alert and what it means in regards to these products:
On September 20th, the FDA came out with a public Alert regarding the potential for neurological adverse events related to flea/tick preventatives within the isoxazoline class – essentially all of the currently available oral flea/tick preventative products (NexGard, Bravecto, Simperica and Credelio).
There are still a lot of unanswered questions presented by the FDA’s Alert, but we are actively investigating this issue and will keep you posted!
It takes energy for the body to maintain immunity against a pathogen, which is a waste in the eyes of the body if that pathogen is no longer considered a threat. Therefore, your body’s immunity against a pathogen will fade over time if it is not re-exposed or “reminded” that the immunity is still important. This is what is being achieved when a vaccine is “boostered” – the body is being reminded that the disease is still important to be protected against.
Do you have a question?
Send us topic you're curious about and we may use it for one of our upcoming blogs!